ZD6474
ZD6474 (also known as Vandetanib or Caprelsa) is a small molecule inhibitor used in the treatment of certain types of cancer. It is a dual inhibitor of EGFR and VEGFR2.
Mechanism of Action[edit | edit source]
ZD6474 works by inhibiting the tyrosine kinases associated with the EGFR and VEGFR2 receptors. This inhibition prevents the activation of these receptors, thereby reducing the growth and proliferation of cancer cells.
Uses[edit | edit source]
ZD6474 is used in the treatment of medullary thyroid cancer and non-small cell lung cancer. It may also be used in the treatment of other types of cancer, as determined by a healthcare provider.
Side Effects[edit | edit source]
Common side effects of ZD6474 include nausea, diarrhea, and rash. More serious side effects may include QT prolongation, interstitial lung disease, and hepatotoxicity.
History[edit | edit source]
ZD6474 was developed by AstraZeneca and was first approved for use in the United States in 2011.
See Also[edit | edit source]
| ZD6474 Resources | |
|---|---|
|
 |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
